Cargando…

Lower serum IgA is associated with COPD exacerbation risk in SPIROMICS

BACKGROUND: Decreased but measurable serum IgA levels (≤70 mg/dL) have been associated with risk for infections in some populations, but are unstudied in COPD. This study tested the hypothesis that subnormal serum IgA levels would be associated with exacerbation risk in COPD. METHODS: Data were anal...

Descripción completa

Detalles Bibliográficos
Autores principales: Putcha, Nirupama, Paul, Gabriel G., Azar, Antoine, Wise, Robert A., O’Neal, Wanda K., Dransfield, Mark T., Woodruff, Prescott G., Curtis, Jeffrey L., Comellas, Alejandro P., Drummond, M. Bradley, Lambert, Allison A., Paulin, Laura M., Fawzy, Ashraf, Kanner, Richard E., Paine, Robert, Han, MeiLan K., Martinez, Fernando J., Bowler, Russell P., Barr, R. Graham, Hansel, Nadia N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5896903/
https://www.ncbi.nlm.nih.gov/pubmed/29649230
http://dx.doi.org/10.1371/journal.pone.0194924
_version_ 1783313882300809216
author Putcha, Nirupama
Paul, Gabriel G.
Azar, Antoine
Wise, Robert A.
O’Neal, Wanda K.
Dransfield, Mark T.
Woodruff, Prescott G.
Curtis, Jeffrey L.
Comellas, Alejandro P.
Drummond, M. Bradley
Lambert, Allison A.
Paulin, Laura M.
Fawzy, Ashraf
Kanner, Richard E.
Paine, Robert
Han, MeiLan K.
Martinez, Fernando J.
Bowler, Russell P.
Barr, R. Graham
Hansel, Nadia N.
author_facet Putcha, Nirupama
Paul, Gabriel G.
Azar, Antoine
Wise, Robert A.
O’Neal, Wanda K.
Dransfield, Mark T.
Woodruff, Prescott G.
Curtis, Jeffrey L.
Comellas, Alejandro P.
Drummond, M. Bradley
Lambert, Allison A.
Paulin, Laura M.
Fawzy, Ashraf
Kanner, Richard E.
Paine, Robert
Han, MeiLan K.
Martinez, Fernando J.
Bowler, Russell P.
Barr, R. Graham
Hansel, Nadia N.
author_sort Putcha, Nirupama
collection PubMed
description BACKGROUND: Decreased but measurable serum IgA levels (≤70 mg/dL) have been associated with risk for infections in some populations, but are unstudied in COPD. This study tested the hypothesis that subnormal serum IgA levels would be associated with exacerbation risk in COPD. METHODS: Data were analyzed from 1,049 COPD participants from the observational cohort study SPIROMICS (535 (51%) women; mean age 66.1 (SD 7.8), 338 (32%) current smokers) who had baseline serum IgA measured using the Myriad RBM biomarker discovery platform. Exacerbation data was collected prospectively (mean 944.3 (SD 281.3) days), and adjusted linear, logistic and zero-inflated negative binomial regressions were performed. RESULTS: Mean IgA was 269.1 mg/dL (SD 150.9). One individual had deficient levels of serum IgA (<7 mg/dL) and 25 (2.4%) had IgA level ≤70 mg/dL. Participants with IgA ≤70 mg/dL were younger (62 vs. 66 years, p = 0.01) but otherwise similar to those with higher IgA. In adjusted models, IgA ≤70 mg/dL was associated with higher exacerbation incidence rates (IRR 1.71, 95% CI 1.01–2.87, p = 0.044) and greater risk for any severe exacerbation (OR 2.99, 95% CI 1.30–6.94, p = 0.010). In adjusted models among those in the lowest decile (<120 mg/dL), each 10 mg/dL decrement in IgA (analyzed continuously) was associated with more exacerbations during follow-up (β 0.24, 95% CI 0.017–0.46, p = 0.035). CONCLUSIONS: Subnormal serum IgA levels were associated with increased risk for acute exacerbations, supporting mildly impaired IgA levels as a contributing factor in COPD morbidity. Additionally, a dose-response relationship between lower serum IgA and number of exacerbations was found among individuals with serum IgA in the lowest decile, further supporting the link between serum IgA and exacerbation risk. Future COPD studies should more comprehensively characterize immune status to define the clinical relevance of these findings and their potential for therapeutic correction.
format Online
Article
Text
id pubmed-5896903
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-58969032018-05-04 Lower serum IgA is associated with COPD exacerbation risk in SPIROMICS Putcha, Nirupama Paul, Gabriel G. Azar, Antoine Wise, Robert A. O’Neal, Wanda K. Dransfield, Mark T. Woodruff, Prescott G. Curtis, Jeffrey L. Comellas, Alejandro P. Drummond, M. Bradley Lambert, Allison A. Paulin, Laura M. Fawzy, Ashraf Kanner, Richard E. Paine, Robert Han, MeiLan K. Martinez, Fernando J. Bowler, Russell P. Barr, R. Graham Hansel, Nadia N. PLoS One Research Article BACKGROUND: Decreased but measurable serum IgA levels (≤70 mg/dL) have been associated with risk for infections in some populations, but are unstudied in COPD. This study tested the hypothesis that subnormal serum IgA levels would be associated with exacerbation risk in COPD. METHODS: Data were analyzed from 1,049 COPD participants from the observational cohort study SPIROMICS (535 (51%) women; mean age 66.1 (SD 7.8), 338 (32%) current smokers) who had baseline serum IgA measured using the Myriad RBM biomarker discovery platform. Exacerbation data was collected prospectively (mean 944.3 (SD 281.3) days), and adjusted linear, logistic and zero-inflated negative binomial regressions were performed. RESULTS: Mean IgA was 269.1 mg/dL (SD 150.9). One individual had deficient levels of serum IgA (<7 mg/dL) and 25 (2.4%) had IgA level ≤70 mg/dL. Participants with IgA ≤70 mg/dL were younger (62 vs. 66 years, p = 0.01) but otherwise similar to those with higher IgA. In adjusted models, IgA ≤70 mg/dL was associated with higher exacerbation incidence rates (IRR 1.71, 95% CI 1.01–2.87, p = 0.044) and greater risk for any severe exacerbation (OR 2.99, 95% CI 1.30–6.94, p = 0.010). In adjusted models among those in the lowest decile (<120 mg/dL), each 10 mg/dL decrement in IgA (analyzed continuously) was associated with more exacerbations during follow-up (β 0.24, 95% CI 0.017–0.46, p = 0.035). CONCLUSIONS: Subnormal serum IgA levels were associated with increased risk for acute exacerbations, supporting mildly impaired IgA levels as a contributing factor in COPD morbidity. Additionally, a dose-response relationship between lower serum IgA and number of exacerbations was found among individuals with serum IgA in the lowest decile, further supporting the link between serum IgA and exacerbation risk. Future COPD studies should more comprehensively characterize immune status to define the clinical relevance of these findings and their potential for therapeutic correction. Public Library of Science 2018-04-12 /pmc/articles/PMC5896903/ /pubmed/29649230 http://dx.doi.org/10.1371/journal.pone.0194924 Text en © 2018 Putcha et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Putcha, Nirupama
Paul, Gabriel G.
Azar, Antoine
Wise, Robert A.
O’Neal, Wanda K.
Dransfield, Mark T.
Woodruff, Prescott G.
Curtis, Jeffrey L.
Comellas, Alejandro P.
Drummond, M. Bradley
Lambert, Allison A.
Paulin, Laura M.
Fawzy, Ashraf
Kanner, Richard E.
Paine, Robert
Han, MeiLan K.
Martinez, Fernando J.
Bowler, Russell P.
Barr, R. Graham
Hansel, Nadia N.
Lower serum IgA is associated with COPD exacerbation risk in SPIROMICS
title Lower serum IgA is associated with COPD exacerbation risk in SPIROMICS
title_full Lower serum IgA is associated with COPD exacerbation risk in SPIROMICS
title_fullStr Lower serum IgA is associated with COPD exacerbation risk in SPIROMICS
title_full_unstemmed Lower serum IgA is associated with COPD exacerbation risk in SPIROMICS
title_short Lower serum IgA is associated with COPD exacerbation risk in SPIROMICS
title_sort lower serum iga is associated with copd exacerbation risk in spiromics
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5896903/
https://www.ncbi.nlm.nih.gov/pubmed/29649230
http://dx.doi.org/10.1371/journal.pone.0194924
work_keys_str_mv AT putchanirupama lowerserumigaisassociatedwithcopdexacerbationriskinspiromics
AT paulgabrielg lowerserumigaisassociatedwithcopdexacerbationriskinspiromics
AT azarantoine lowerserumigaisassociatedwithcopdexacerbationriskinspiromics
AT wiseroberta lowerserumigaisassociatedwithcopdexacerbationriskinspiromics
AT onealwandak lowerserumigaisassociatedwithcopdexacerbationriskinspiromics
AT dransfieldmarkt lowerserumigaisassociatedwithcopdexacerbationriskinspiromics
AT woodruffprescottg lowerserumigaisassociatedwithcopdexacerbationriskinspiromics
AT curtisjeffreyl lowerserumigaisassociatedwithcopdexacerbationriskinspiromics
AT comellasalejandrop lowerserumigaisassociatedwithcopdexacerbationriskinspiromics
AT drummondmbradley lowerserumigaisassociatedwithcopdexacerbationriskinspiromics
AT lambertallisona lowerserumigaisassociatedwithcopdexacerbationriskinspiromics
AT paulinlauram lowerserumigaisassociatedwithcopdexacerbationriskinspiromics
AT fawzyashraf lowerserumigaisassociatedwithcopdexacerbationriskinspiromics
AT kannerricharde lowerserumigaisassociatedwithcopdexacerbationriskinspiromics
AT painerobert lowerserumigaisassociatedwithcopdexacerbationriskinspiromics
AT hanmeilank lowerserumigaisassociatedwithcopdexacerbationriskinspiromics
AT martinezfernandoj lowerserumigaisassociatedwithcopdexacerbationriskinspiromics
AT bowlerrussellp lowerserumigaisassociatedwithcopdexacerbationriskinspiromics
AT barrrgraham lowerserumigaisassociatedwithcopdexacerbationriskinspiromics
AT hanselnadian lowerserumigaisassociatedwithcopdexacerbationriskinspiromics
AT lowerserumigaisassociatedwithcopdexacerbationriskinspiromics